Sunday 18 October 2026
Export NERV’s income statement to Excel — free account
Minerva Neurosciences, Inc
NERV Healthcare Biotechnology
In the quarter to June 2026, EPS grew 183.7% and free cash flow fell 553.5%, each against the same quarter a year earlier.
2.35
0.07
−2.89%
Follow NERV
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | 29.25 | — | — | — | — |
Altman Z-Score |
— | — | — | — | — | 5.95 | — | — | — | — |
P/S ratio |
— | — | — | — | — | 0.00 | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | (1.99) | — | — | — | — |
P/FCF ratio |
— | — | — | — | — | 0.00 | — | — | — | — |
P/Operating CF |
— | — | — | — | — | (13.34) | — | — | — | — |
P/B ratio |
— | — | — | — | — | 1.81 | — | — | — | — |
Price to Tangible BV |
— | — | — | — | — | 2.53 | — | — | — | — |
EV/Sales |
— | — | — | — | — | 0.00 | — | — | — | — |
EV/EBITDA |
— | — | — | — | — | 37.91 | — | — | — | — |
EV/Operating CF |
— | — | — | — | — | (2.17) | — | — | — | — |
EV/FCF |
— | — | — | — | — | (2.16) | — | — | — | — |
Quick Ratio |
35.98 | 7.57 | 12.28 | 26.27 | 21.59 | 8.06 | 6.93 | 24.41 | 18.75 | 8.58 |
Current Ratio |
36.28 | 7.85 | 12.57 | 29.15 | 22.07 | 8.68 | 7.11 | 24.94 | 18.94 | 8.66 |
Net Debt/EBITDA |
5.46 | 0.98 | 1.78 | 1.44 | 1.34 | (13.15) | 0.60 | 1.70 | 3.12 | 2.67 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 2.89% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.61 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.05 | (13.59) | 0.49 | 0.77 | 0.49 | (17.43) | 0.60 | 0.84 | (0.10) | 0.83 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (1.92) | 0.00 | 0.00 | 0.00 | 0.00 | (1.63) | 0.00 |
Interest Coverage |
— | — | — | (45.31) | (2,749.44) | 11.46 | (52.11) | (468.57) | (67.02) | (29.32) |
| 352.58% | (5.31%) | 123.78% | 532.98% | (164.60%) | 4.83% | (122.30%) | (45.23%) | (26.54%) | (38.49%) | |
| (434.34%) | 3.06% | (53.59%) | (48.57%) | (74.07%) | 2.87% | (66.64%) | (31.08%) | (19.91%) | (28.81%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 4.24% | 0.00% | (1,491.63%) | (766.68%) | (70.51%) |
Return on Tangible Assets |
(363.11%) | 7.40% | (77.59%) | (82.76%) | (83.97%) | 4.92% | (129.54%) | (41.59%) | (20.08%) | (28.64%) |
Average Days of Receivables |
— | — | — | 0.00 | — | 0.00 | — | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 53.53% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 41.99% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.15 | 0.40 | 0.26 | 0.27 | 0.19 | 0.26 | 0.19 | 0.11 | 0.08 | 0.11 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 23.57% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | — | — | — | — | 0.24 | — | — | — | — |
Graham Number |
— | — | — | — | — | 12.19 | — | — | — | — |
Earnings Yield |
— | — | — | — | — | 3.42% | — | — | — | — |
Free Cash Flow Yield |
— | — | — | — | — | (35.51%) | — | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.07 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.60) | (2.58) | (2.27) | (4.61) | (4.61) | (6.63) | (8.91) | (8.65) | 0.65 | (6.52) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.01) | 0.00 |
Free Cash Flow per Share |
(1.60) | (2.58) | (2.27) | (4.62) | (4.61) | (6.63) | (8.91) | (8.65) | 0.64 | (6.52) |
Cash per Share |
9.74 | 2.84 | 6.30 | 6.78 | 11.40 | 4.99 | 9.42 | 18.17 | 27.04 | 21.09 |
Shareholders Equity per Share |
(16.63) | (3.39) | (4.37) | (3.75) | 1.49 | 10.32 | 5.70 | 18.61 | 27.75 | 26.90 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(16.63) | (3.39) | (4.37) | (3.75) | 1.49 | 10.32 | 5.70 | 18.61 | 27.75 | 26.90 |
Free Cash Flow |
(13.51) | (19.55) | (14.78) | (24.66) | (24.60) | (33.82) | (43.43) | (41.94) | 3.04 | (25.69) |
Working Capital |
80.81 | 19.43 | 38.66 | 38.78 | 59.38 | 24.28 | 40.51 | 86.41 | 122.70 | 74.18 |
Capital Expenditures |
— | — | — | (0.02) | — | — | — | — | (0.05) | — |
Net Current Asset Value |
(155.62) | (40.57) | (43.35) | (34.95) | (6.94) | 22.48 | (2.58) | 41.15 | 77.44 | 56.90 |
EV/EBIT |
— | — | — | — | — | 39.75 | — | — | — | — |
Capex to Sales |
— | — | — | 0.00 | — | 0.00 | — | — | 0.00 | — |
Price to Operating Income |
— | — | — | — | — | 51.73 | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 4.17 | 2.84 | 0.52 | 1.99 | 0.01 | (0.04) | 0.00 | 0.00 | 0.01 |
Cash ROIC |
23.16% | 462.07% | (117.76%) | (152.52%) | (35.74%) | (43.30%) | (58.90%) | (23.51%) | 1.17% | (13.32%) |
Accounts Receivable Turnover |
— | — | — | — | — | 0.00 | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
1.12 | 1.71 | 1.39 | 1.41 | 1.42 | 1.66 | 2.06 | 1.62 | 1.45 | 1.41 |
Average Assets |
67.56 | 47.02 | 55.99 | 66.10 | 67.37 | 67.56 | 108.32 | 161.42 | 158.32 | 107.76 |
Average Common Equity |
(83.22) | (27.08) | (24.24) | (6.02) | 30.32 | 40.22 | 59.02 | 110.93 | 118.79 | 80.65 |
Columns are period end dates